Photo by _louisreed from unsplash
MAGNIFY PHASE IIIB INTERIM ANALYSIS: FIRST REPORT OF INDUCTION R FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA J. Sharman | M. Coleman | A. Yacoub | J.… Click to show full abstract
MAGNIFY PHASE IIIB INTERIM ANALYSIS: FIRST REPORT OF INDUCTION R FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA J. Sharman | M. Coleman | A. Yacoub | J. Melear | S. Fanning | K. Kolibaba | F. Lansigan | C. Reynolds | K. Foon | J. Li | M. Llorente | M. Rummel | D. Andorsky Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, United States; Clinical Research Alliance Inc., Weill Cornell Medicine, New York, United States; Hematology, University of Kansas Cancer Center, Westwood, United States; Texas Oncology – Austin, US Oncology Research, Austin, United States; Greenville Health System, US Oncology Research, Greenville, United States; Compass Oncology, US Oncology Research, Vancouver, United States; Hematology, Dartmouth–Hitchcock Medical Center, Lebanon, United States; Hematology, IHA Hematology Oncology Consultants – Ann Arbor, Ypsilanti, United States; Global Medical Affairs, Celgene Corporation, Summit, United States; BioStatistics, Celgene Corporation, Summit, United States; Hematology, Justus-Liebig Universität, Giessen, Germany; Rocky Mountain Cancer Centers, US Oncology Research, Boulder, United States
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!